Passage Bio to Participate in Upcoming March Investor Conferences
Passage Bio (NASDAQ: PASG) announced participation in two virtual investor conferences in March 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Passage Bio (NASDAQ: PASG) announced participation in two virtual investor conferences in March 2021. The first is the Barclay’s Global Healthcare Conference on March 10, at 4:10 p.m. ET, featuring a presentation format. The second event is the Stifel 3rd Annual CNS Day on March 31, at 10:00 a.m. ET, in a fireside chat format. Both events will be webcast live, with replays available for 30 days. Passage Bio focuses on gene therapies for rare central nervous system disorders, collaborating with the University of Pennsylvania's Gene Therapy Program.
Details
News Market Reaction – PASG
The recorded move for PASG in the trading session of this news was +1.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in March:
Barclay’s Global Healthcare Conference
Format: Presentation
Date: Wednesday, March 10, 2021
Time: 4:10 p.m. ET
Stifel 3rd Annual CNS Day
Format: Fireside Chat
Date: Wednesday, March 31, 2021
Time: 10:00 a.m. ET
A live webcast of the presentation and fireside chat will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the Barclay's and Stifel presentations will be available for 30 days following the fireside chat.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.